<scp>Open‐Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy

Abstract

Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.